



Docket No. 0263-4047

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Sumida, Shuji

Group Art Unit: 1653

Serial No.: 09/622,487

Examiner: Moezie, F.

Filed: August 17, 2000

For: PROTEIN-FREE FORMULATIONS

AMENDMENT FEE TRANSMITTAL

Commissioner for Patents
Washington, DC 20231

RECEIVED

MAR 14 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an Amendment for the above-identified application.

No additional fee is required.
 The additional fee has been calculated as shown below:

CLAIMS AS AMENDED.

| | Claims Remaining After Amendment | Highest No. Covered by Previous Payments | Extra | Rate | Additional Fee |
|---------------------------|---|--|-------|------------------|----------------|
| Total Claims* | - | 20 | 0 | \$18.00/ \$9.00 | \$ 0.00 |
| Independent Claims | - | 3 | 0 | \$84.00/ \$42.00 | \$ 0.00 |
| Multiple Dependent Claims | (If claims added by amendment include Multiple Dependent Claim(s) and there was no Multiple Dependent Claim(s) in application before amendment add \$280.00 to additional fee (\$140.00 for small entity).) | | | | |
| TOTAL | | | | | \$ 0.00 |

*Includes all independent and single dependent claims and all claims referred to in multiple dependent claims. See 37 C.F.R. §1.75(c).


Small entity status is or has been claimed.
Reduced Fees Under 37 C.F.R. §1.9(f) paid herewith \$

- _____ Pages Sequence Listing
- _____ Computer disk(s) containing substitute Sequence Listing
- Statement under 37 C.F.R. §1.825(b) that the computer and paper copies of the substitute Sequence Listing are the same.
- A check in the amount of \$_____ to cover the filing fee is attached.
- Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- The Commissioner is hereby authorized to charge any additional fees which may be required for filing this amendment, including all fees pursuant to 37 CFR §1.17 for its timely consideration, or credit any overpayment to Deposit Account No. 13-4500, Order No. 0263-4047. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: February 25, 2002

By:



Eugene Moroz
Registration No. 25,237

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



PATENT
Docket No. 0263-4047

47/A
3/27/02
RJL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shuji SUMIDA and Yasushi SATO

Serial No.: 09/622,487 Art Unit : 1653

Filed : August 17, 2000 Examiner: Moezie, F.

For : PROTEIN FREE FORMULATIONS

Commissioner For Patents
Washington D.C. 20231

RECEIVED
MAR 14 2002
TECH CENTER 1600/2900

AMENDMENT AND RESPONSE

Sir:

This correspondence is in response to the Office Action dated August 24, 2001 for the above-identified application. Prior to entry of this Amendment and Response, claims 1-12 were pending in this application.

Please amend the application as follows:

IN THE CLAIMS:

Please withdraw Claims 6 and 9 without prejudice.

Please amend Claims 1 and 7 to read as follows:

1. A stable granulocyte colony-stimulating factor-containing formulation comprising a granulocyte colony-stimulating factor having a sugar chain and at least one pharmaceutically acceptable non-ionic surfactant in an amount of 1 part by weight or less per part by weight of the granulocyte colony-stimulating factor and having a pH of 5-7, said formulation being substantially free from protein as a stabilizer.

pur B17
RJL